HHS unveiled a blueprint Monday to fast-track early-stage drug trials in the US, aiming to shave 6 to 12 months off development timelines — and the unsubtle target is China. The plan pairs drug sponsors with research institutions to streamline Investigational New Drug applications, cutting unnecessary toxicology and manufacturing documentation. Acting FDA Commissioner Kyle Diamantas told reporters the agency will also affirm that a single, high-quality Phase 3...